# Targeted Pathway Inhibition in Patients With Pancreatic Cancer

> **NCT04005690** · EARLY_PHASE1 · RECRUITING · sponsor: **OHSU Knight Cancer Institute** · enrollment: 90 (estimated)

## Conditions studied

- Locally Advanced Pancreatic Ductal Adenocarcinoma
- Metastatic Pancreatic Ductal Adenocarcinoma
- Stage II Pancreatic Cancer AJCC v8
- Stage III Pancreatic Cancer AJCC v8
- Stage IV Pancreatic Cancer AJCC v8
- Unresectable Pancreatic Ductal Adenocarcinoma
- Borderline Resectable Pancreatic Ductal Adenocarcinoma
- Resectable Pancreatic Ductal Adenocarcinoma

## Interventions

- **DRUG:** Cobimetinib
- **DRUG:** Olaparib
- **DRUG:** Onvansertib
- **DRUG:** Azenosertib
- **DRUG:** Saruparib
- **BIOLOGICAL:** Tremelimumab

## Key facts

- **NCT ID:** NCT04005690
- **Lead sponsor:** OHSU Knight Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2019-08-01
- **Primary completion:** 2026-06-01
- **Final completion:** 2028-02-01
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2026-02-27

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04005690

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04005690, "Targeted Pathway Inhibition in Patients With Pancreatic Cancer". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT04005690. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*